Literature DB >> 16344437

Blepharokeratoconjunctivitis in children.

Kristin M Hammersmith1, Elisabeth J Cohen, Timothy D Blake, Peter R Laibson, Christopher J Rapuano.   

Abstract

OBJECTIVE: To evaluate the incidence, history, symptoms, clinical signs, and treatment outcomes of blepharokeratoconjunctivitis in a pediatric population at a tertiary cornea practice.
METHODS: In a retrospective case series, we reviewed the medical records of all new pediatric patients from January 1, 1997, through December 31, 2002, noting the reason for referral and subsequent diagnosis. We further noted the history, clinical characteristics, and treatment outcomes of the patients with blepharokeratoconjunctivitis.
RESULTS: Review of 195 medical records revealed that blepharokeratoconjunctivitis was the most common single diagnosis at consultation, accounting for 15% of referrals. Of the 29 cases identified, there were 16 girls (55%) and 13 boys (45%). The mean age at consultation was 6(1/2) years (age range, 2-12 years). On initial ophthalmologic examination, 11 (38%) of 29 patients were taking full-strength steroids and 4 patients (14%) were taking oral erythromycin. Oral therapy, in the form of erythromycin (n = 21) and doxycycline (n = 1), was prescribed to most patients (22/29 [76%]). Therapy with topical steroids was tapered at the initial visit in all patients. Follow-up was available for 15 of 29 patients, with a mean follow-up of 5.4 months (range, 2-25 months). The condition of all patients showed clinical improvement. Recurrences were noted in 6 (40%) or 15 patients; all were successfully managed with low-potency steroid therapy.
CONCLUSIONS: Blepharokeratoconjunctivitis is a common reason for cornea referral in children. Oral erythromycin therapy is an effective treatment with a steroid-sparing effect. Recurrences are common and may be successfully managed with low-potency steroid therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344437     DOI: 10.1001/archopht.123.12.1667

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

Review 1.  Topical treatments for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Catey Bunce; Melanie Hingorani; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2017-02-07

Review 2.  [Chronic blepharitis. Pathogenesis, clinical features, and therapy].

Authors:  C Auw-Haedrich; T Reinhard
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

3.  Blepharokeratoconjunctivitis in childhood: corneal involvement and visual outcome.

Authors:  A Rodríguez-García; S González-Godínez; S López-Rubio
Journal:  Eye (Lond)       Date:  2015-12-04       Impact factor: 3.775

4.  Oral azithromycin combined with topical anti-inflammatory agents in the treatment of blepharokeratoconjunctivitis in children.

Authors:  Daniel S Choi; Ali Djalilian
Journal:  J AAPOS       Date:  2013-01-27       Impact factor: 1.220

Review 5.  Systemic treatment for blepharokeratoconjunctivitis in children.

Authors:  Michael O'Gallagher; Marina Banteka; Catey Bunce; Frank Larkin; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2016-05-30

6.  A Phase III clinical study to evaluate the efficacy of combined azithromycin and dexamethasone in the treatment of blepharoconjunctivitis.

Authors:  Kamran Hosseini; Judith Hutcheson; Richard L Lindstrom
Journal:  Clin Ophthalmol       Date:  2013-11-11

7.  Evaluation of the ocular surface characteristics and Demodex infestation in paediatric and adult blepharokeratoconjunctivitis.

Authors:  Mengliang Wu; Xiaochun Wang; Jing Han; Tingting Shao; Yan Wang
Journal:  BMC Ophthalmol       Date:  2019-03-07       Impact factor: 2.209

8.  Efficacy of azithromycin 1.5% eye drops in childhood ocular rosacea with phlyctenular blepharokeratoconjunctivitis.

Authors:  Serge Doan; Eric Gabison; Frédéric Chiambaretta; Melissa Touati; Isabelle Cochereau
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.